Get started
MannKind CorporationMannKind CorporationMannKind Corporation

MannKind Corporation

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

MNKD chart


Full chart

MNKD upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.90 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
97.58
Basic EPS (TTM)
0.08 USD
Net income (FY)
‪−11.94 M‬ USD
Revenue (FY)
‪198.96 M‬ USD
Shares float
‪267.25 M‬
Beta (1Y)
1.01

Employees


Employees (FY)
414
Change (1Y)
+19 +4.81%
Revenue / Employee (1Y)
‪480.58 K‬ USD
Net income / Employee (1Y)
‪−28.84 K‬ USD

About MannKind Corporation


Sector
Health Technology
CEO
Michael E. Castagna
Headquarters
Danbury
Website
mannkindcorp.com
Founded
1991
FIGI
BBG000PPL3G9
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

MNKD news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

MNKD highest yielding bonds


MNKD5380745
MannKind Corporation 2.5% 01-MAR-2026
Yield to maturity
−19.83%
Maturity date
Mar 1, 2026

Explore more bonds 

Frequently Asked Questions


The current price of MNKD is 6.91 USD — it has increased by 0.29% in the past 24 hours. Watch MannKind Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange MannKind Corporation stocks are traded under the ticker MNKD.
MNKD stock has fallen by −3.37% compared to the previous week, the month change is a 4.72% rise, over the last year MannKind Corporation has showed a 86.23% increase.
We've gathered analysts' opinions on MannKind Corporation future price: according to them, MNKD price has a max estimate of 12.00 USD and a min estimate of 7.00 USD. Watch MNKD chart and read a more detailed MannKind Corporation stock forecast: see what analysts think of MannKind Corporation and suggest that you do with its stocks.
MNKD reached its all-time high on Sep 24, 2004 with the price of 121.55 USD, and its all-time low was 0.67 USD and was reached on May 3, 2017. View more price dynamics on MNKD chart.
See other stocks reaching their highest and lowest prices.
MNKD stock is 3.56% volatile and has beta coefficient of 1.01. Track MannKind Corporation stock price on the chart and check out the list of the most volatile stocks — is MannKind Corporation there?
Today MannKind Corporation has the market capitalization of ‪1.90 B‬, it has decreased by −1.99% over the last week.
Yes, you can track MannKind Corporation financials in yearly and quarterly reports right on TradingView.
MannKind Corporation is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
MNKD earnings for the last quarter are 0.04 USD per share, whereas the estimation was 0.03 USD resulting in a 33.33% surprise. The estimated earnings for the next quarter are 0.03 USD per share. See more details about MannKind Corporation earnings.
MannKind Corporation revenue for the last quarter amounts to ‪70.08 M‬ USD, despite the estimated figure of ‪73.31 M‬ USD. In the next quarter, revenue is expected to reach ‪74.01 M‬ USD.
MNKD net income for the last quarter is ‪11.55 M‬ USD, while the quarter before that showed ‪−2.01 M‬ USD of net income which accounts for 673.49% change. Track more MannKind Corporation financial stats to get the full picture.
No, MNKD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 414.00 employees. See our rating of the largest employees — is MannKind Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MannKind Corporation EBITDA is ‪65.12 M‬ USD, and current EBITDA margin is 8.24%. See more stats in MannKind Corporation financial statements.
Like other stocks, MNKD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MannKind Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MannKind Corporation technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MannKind Corporation stock shows the buy signal. See more of MannKind Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.